Glatiramer Acetate (Copaxone) Modulates Platelet Activation and Inhibits Thrombin-Induced Calcium Influx: Possible Role of Copaxone in Targeting Platelets during Autoimmune Neuroinflammation by Starossom, Sarah C. et al.
 
Glatiramer Acetate (Copaxone) Modulates Platelet Activation and
Inhibits Thrombin-Induced Calcium Influx: Possible Role of
Copaxone in Targeting Platelets during Autoimmune
Neuroinflammation
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Starossom, Sarah C., Tatyana Veremeyko, Marina Dukhinova,
Amanda W. Y. Yung, and Eugene D. Ponomarev. 2014.
“Glatiramer Acetate (Copaxone) Modulates Platelet Activation
and Inhibits Thrombin-Induced Calcium Influx: Possible Role of
Copaxone in Targeting Platelets during Autoimmune
Neuroinflammation.” PLoS ONE 9 (5): e96256.
doi:10.1371/journal.pone.0096256.
http://dx.doi.org/10.1371/journal.pone.0096256.
Published Version doi:10.1371/journal.pone.0096256
Accessed February 16, 2015 1:11:08 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407035
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAGlatiramer Acetate (Copaxone) Modulates Platelet
Activation and Inhibits Thrombin-Induced Calcium
Influx: Possible Role of Copaxone in Targeting Platelets
during Autoimmune Neuroinflammation
Sarah C. Starossom
1,2, Tatyana Veremeyko
3, Marina Dukhinova
3, Amanda W. Y. Yung
3,
Eugene D. Ponomarev
1,3*
1Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 2Institute for Medical
Immunology and NeuroCure, Charite ´ - Universita ¨tsmedizin Berlin, Berlin, Germany, 3School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, NT,
Hong Kong
Abstract
Background: Glatiramer acetate (GA, Copaxone, Copolymer-1) is an FDA approved drug for the treatment of MS and it is
very effective in suppressing neuroinflammation in experimental autoimmune encephalitis (EAE), an animal model of MS.
Although this drug was designed to inhibit pathogenic T cells, the exact mechanism of EAE/MS suppression by GA is still not
well understood. Previously we presented evidence that platelets become activated and promote neuroinflammation in
EAE, suggesting a possible pathogenic role of platelets in MS and EAE. We hypothesized that GA could inhibit
neuroinflammation by affecting not only immune cells but also platelets.
Methodology/Principal Findings: We investigated the effect of GA on the activation of human platelets in vitro: calcium
influx, platelet aggregation and expression of activation markers. Our results in human platelets were confirmed by in-vitro
and in-vivo studies of modulation of functions of platelets in mouse model. We found that GA inhibited thrombin-induced
calcium influx in human and mouse platelets. GA also decreased thrombin-induced CD31, CD62P, CD63, and active form of
aIIbb3 integrin surface expression and formation of platelet aggregates for both mouse and human platelets, and
prolonged the bleeding time in mice by 2.7-fold. In addition, we found that GA decreased the extent of macrophage
activation induced by co-culture of macrophages with platelets.
Conclusions: GA inhibited the activation of platelets, which suggests a new mechanism of GA action in suppression of EAE/
MS by targeting platelets and possibly preventing their interaction with immune cells such as macrophages. Furthermore,
the reduction in platelet activation by GA may have additional cardiovascular benefits to prevent thrombosis.
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Introduction
Platelets play an important role in cardiovascular pathologies,
but their role in neuroinflammatory diseases is not clear [1–3].
Recently it was demonstrated that platelets contributed to
inflammation during rheumatoid arthritis and arthrosclerosis [4–
6]. Activated platelets produce a number of pro-inflammatory
mediators (cytokines, chemokines, histamin etc.) and could initiate
and propagate inflammation [7]. It was demonstrated that
platelets become activated during multiple sclerosis (MS) [8]. It
was also reported that in MS patients there were increased
numbers of platelet aggregates, platelet-derived microparticles and
increased levels of the activation marker CD62P on the surface of
platelets [9]. We and other group have demonstrated that the
depletion of platelets substantially ameliorated central nervous
system (CNS) autoimmune inflammation during experimental
autoimmune encephalitis (EAE), an animal model of MS [10,11].
Our previous study demonstrated that during EAE platelets
become activated by sialated glycolipids integrated into neuronal
and astroglial lipid rafts found in blood brain barrier structures,
which was critical for the development of CNS autoimmune
inflammation [11].
Currently IFN-b and glatiramer acetate (GA) are the most
commonly used FDA-approved drugs for MS therapy [12].
Although it was well established that the cytokine IFN-b plays
an immunomodulatory and regulatory role, much less is known
about the mechanisms of actions of GA. Among the proposed
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frequency of MS relapses is the deactivation of myelin specific T
cells and skewing CD4 T cells differentiation form pathological
Th1 towards regulatory Th2 phenotypes [12]. In addition, it was
proposed that GA affects innate immune cells including macro-
phages and dendritic cells [13,14]. Particularly it was shown that
GA influence monocyte/macrophage polarization by shifting the
balance from pathological M1 towards the more regulatory M2
phenotypes [13]. Finally it was recently proposed that GA affected
B cells [15,16]. Despite the emerging evidence for great
importance of platelets in MS pathophysiology, the possible action
of GA on platelet functions has not been investigated so far.
It was shown that in several cases of treatment of MS patients,
subcutaneous injections of IFN-b resulted in thrombosis in
cutaneous venules leading to the formation of skin lesions [17].
Formation of skin lesions were also reported for GA injections
[18], suggesting possible involvements of both drugs in modulation
of platelet functions. Given the fact that MS patients often
demonstrated other platelet abnormalities such as thrombocyto-
penia [19], we decided to investigate possible actions of GA and
IFN-b on their capacity to modulate platelet functions.
In this study we found that GA, but not IFN-b, substantially
inhibited thrombin-induced activation of human and mouse
platelets, as was demonstrated by substantial reduction in the
level of Ca
2+ influx, a hallmark of platelet activation. Furthermore,
our investigation demonstrated a strong inhibitory effect of GA on
platelet activation as determined by the reduction in aggregate
formation and a decrease in surface expression of CD62P and
other platelet activation markers, which indicates a new mecha-
nism of GA action during MS therapy.
Results
GA inhibites Ca
2+ influx in human thrombin-activated
platelets
In the first series of experiments we tested whether commonly
used FDA-approved drugs for multiple sclerosis GA (Copaxo-
ne
TM) and IFN-b (Betaseron
TM) affected platelet functions as
determined by measurement of thrombin-induced Ca2+ influx, an
established hallmark of platelet activation. We investigated various
doses of GA and IFN-b to determine whether they affect Ca2+
influx in thrombin-stimulated platelets isolated from normal
healthy subjects. Calcium influx was measured by the calcium-
specific fluorescence probe Fura-2M that detects intracellular
concentration of Ca2+. We found that at optimal concentrations
for GA (100 mg/ml) and IFN-b (100 U/ml), pretreatment of
human platelets for 30 min with GA significantly decreased Ca2+
influx in thrombin-activated platelets (Fig. 1A; PBS/Thrombin
and GA/Thrombin), whereas IFN-b enhanced it, although the
increase was not statistically significant (Fig. 1A; PBS/Thrombin
and IFNb/Thrombin). In contrast to IFN-b, the effect of the
inhibition of Ca2+ influx in thrombin-activated platelets by GA
was statistically significant for all measured time-points (Fig. 1A;
PBS/Thrombin and GA/Thrombin). Inhibition of Ca2+ influx
was observed for the range of concentrations of GA from 20 to
200 mg/ml with the strongest effect for concentration of 50–
100 mg/ml (not shown). Thus, GA strongly affected functions of
human platelets by inhibiting thrombin-induced Ca2+ influx. We
also tested whether GA affects functions of mouse platelets and
found that GA inhibited Ca2+ influx in thrombin-activated mouse
platelets as well (Fig. 1B). This indicates that GA inhibits
thrombin-induced Ca2+ influx in both human and mouse
platelets.
GA inhibits upregulation of CD62P and other activation
markers in human and mouse thrombin-activated
platelets
We further investigated how GA affects thrombin-induced
platelet activation in human and mouse platelets in vitro.I n
addition to calcium signaling, it was shown that activated platelets
upregulated CD62P on their surface, which was investigated by
flow cytometry. We found that the baseline level of CD62P in
human platelets varied (with up-to 8-fold difference for mean
fluorescence intensity (MFI) levels) among different examined
subjects (N=17; not shown) and was typically from low to
intermediate levels as shown in one of the representative
experiments (Fig 2B; Unstimulated). Platelets form unmanipulated
mice had low level of CD62P (Fig. 2A; Unstimulated), demonstrat-
ing their non-activated status. Activation of platelets with
thrombin induced upregulation of CD62P in both human and
mouse platelets (Fig. 2A and Fig. 2B; PBS/Thrombin). However
pre-treatment of human or mouse platelets with GA at concen-
tration 20–200 mg/ml diminished CD62P upregulation with the
strongest effect of 100 mg/ml for human and 50 mg/ml for mouse
Figure 1. Analysis of effects of glatiramer acetate and IFN-b on
thrombin-induced calcium influx in human and mouse plate-
lets. Human (A) or mouse (B) platelets were isolated as described in
Methods and pre-treated with glatiramer acetate (GA; 50–100 mg/ml), or
IFN-b (100 U/ml), or PBS for 30 min, after which thrombin (0.1 U/ml) or
PBS were added as indicated by arrow. Fluorescent probe Fura-2M was
used to measure intracellular Ca
2+ as described in Methods.( A) The
relative level of changes in Fura-2M fluorescence (y-axis) vs. time (x-axis)
is shown for human platelets pretreated with GA, IFN-b or PBS and then
treated with thrombmin (GA/Thrombin, IFNb/Thrombin,a n dPBS/
Thrombin) or PBS (GA/PBS, IFNb/PBS, and PBS/PBS). Mean 6 S.E. of four
separate experiments is shown. (*, p,0.05 and **, p,0.01 for PBS/
Thrombin vs. GA/Thrombin). (B) The relative level of changes in Fura-2M
fluorescence (y-axis) vs. time (x-axis) is shown for mouse platelets
pretreated with GA or PBS and then activated with thrombmin. Mean 6
S.E. of triplicate is shown.
doi:10.1371/journal.pone.0096256.g001
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which was consistent with our data on Ca
2+ influx. The inhibitions
of CD62P expression at optimal doses (50 and 100 mg/ml) were
statistically significant for both, human and mouse platelets
(Table 1, CD62P). At the concentration of 500 mg/ml or higher,
GA had little/no effect or even enhanced CD62P expression,
suggesting that at a high doses of GA could activate platelets by
increasing CD62P expression (Fig. 2A and Fig. 2B; GA(500 mg/
ml)/Thrombin). Thus we found that at the optimal range of
concentrations, GA inhibited platelet activation as determined by
CD62P expression level; however at a very high concentrations (.
500 mg/ml) GA increased platelet activation as determined by
upregulation of CD62P. We further investigated expression of
other activation markers for human and mouse platelets. We
found that at concentration of 50–100 mg/ml GA decreased MFI
levels of active form of aIIbb3 integrin and CD63 by 4365% and
5764%, respectively for thrombin-activated human platelets (Fig.
S1), and decreased ,2-fold MFI levels of active form aIIbb3
integrin and CD31 for thrombin-activated mouse platelets (Fig. 3).
Thus, GA decreased expression of all examined activation markers
on the surface of thrombin-activated human and mouse platelets.
GA inhibits aggregate formation of human and mouse
thrombin-activated platelets
Next we investigated the effect of GA on thrombin-induced
platelet aggregate formation. Similarly to CD62P expression, GA
decreased the percentages of aggregated platelets with the
strongest effect at concentrations of 100 mg/ml for human
(Fig. 4A) and 50 mg/ml for mouse palettes (Fig. 4B). At the high
concentrations (500 mg/ml), the percentage of aggregated platelets
was even increased in case of mouse platelets (Fig. 4B). The
increase in aggregate formation by very high concentrations of GA
was again consistent with CD62P expression (Fig. 2). The
inhibition of platelet aggregate formation at optimal concentra-
tions of 50 and100 mg/ml were statistically significant for mouse
and human platelets, respectively (Table 1, Aggregates). Thus at
concentrations of 50–200 mg/ml GA decreased platelet activation
as determined by aggregate formation. Similarly to CD62P
expression, high concentrations of GA (.500 mg/ml) increased
platelet aggregation. We confirmed inhibitory effect of GA on
platelet aggregate formation in another assay where platelets
adhered to collagen and aggregated under flow conditions. At
concentration of 50 and 100 mg/ml, GA substantially decreased
formation of platelet aggregates under flow conditions by
decreasing 6–8-fold the average size of thrombi (Fig. 5).
Finally we investigated whether IFN-b affects expression of
CD62P on the surface of thrombin-activated platelets and their
aggregate formation. We found that at the concentration of 100U/
ml IFN-b enhanced thrombin-induced expression of CD62P (Fig.
S2), but did not affect platelet aggregate formation as determined
by FACS (not shown). Thus we found that GA, but not IFN-b,
inhibited platelet functions as determined by decrease in
expression of activation markers and reduction in aggregate
formation.
GA affects interaction of platelets with macrophages in
vitro
We and others have found that depletion of platelets
ameliorated neuroinflammation in animal model of MS [10,11].
It was also proposed that platelets could interact with macrophages
and promote their activation and migration to the site of
inflammation [20,21]. Based on this, it was hypothesized that
interaction of platelets with immune cells such as macrophages is
one of the major mechanisms of initiation and perpetuation of
neuroinflammation by platelets [10,11]. To test whether GA affect
interaction of platelets with immune cells such as macrophages, we
co-cultured macrophages with autologous platelets in the presence
of GA. We found that platelets contributed macrophage activation
in vitro as determined by upregulation of two examined macro-
phage activation markers: co-stimulatory molecule CD86 and
MHC class II (Fig. 6). Addition of GA to co-cultured macro-
phages and platelets significantly decreased platelet-induced
upregulation of CD86 and MHC class II on macrophages. Thus,
GA decreased platelet-mediated activation of macrophages.
Figure 2. Effect of glatiramer acetate (GA) on thrombin-
induced surface expression of CD62P in human and mouse
platelets. Human (A) or mouse (B) platelets were isolated as described
in Methods and were pretreated with PBS or various concentrations of
glatiramer acetate (GA; 20–500 mg/ml) for 30 min. After pretreatment
with GA, platelets were activated with thrombin and then analyzed by
FACS as described in Methods. Histograms for CD62P (solid lines) or
isotype control (dotted lines) expressions are shown for CD42a
+CD61
+
gated human (A) or CD41
+CD61
+ gated mouse (B) platelets. Mean
fluorescent intensity (MFI) for CD62P expression is shown in upper right
corner of each histogram. Representative experiment of five is shown.
doi:10.1371/journal.pone.0096256.g002
Copaxone Inhibits Platelet Activation
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e96256GA prolongs bleeding time in vivo
Since we found that GA had a similar inhibitory effect on both
human (Fig. 2A and Fig. 4A) and mouse (Fig. 2B and Fig. 4B)
platelets, we further tested the effect of GA on murine platelets in
vivo. One of the commonly used rodent models to test the platelet
functions in vivo is the tail bleeding test [22]. If the activation of
platelets is inhibited, bleeding time increases as we described in
our previous study [11]. Indeed we found that i.v. and s.c.
administration of GA (see Methods) significantly increased the
bleeding time, suggesting an inhibitory effect of GA on platelet
activation in vivo. At the same time i.v. administration of IFN-b did
not have any statistically significant effects on tail bleeding time
(Fig. 7). Thus GA, but not IFN-b, inhibited platelet activation in
vivo in mouse model of tail bleeding.
Discussion
In this study we investigated the effect of GA on platelet
physiology in vitro and in vivo. We found that GA modulates platelet
functions by decreasing their level of activation and thus leading to
an increased bleeding time in vivo. This observation is of particular
importance, as the exact mechanisms of therapeutic effect of GA
in MS are still not fully understood and the effects of GA on
platelets have not been reported yet.
Figure 3. Effect of glatiramer acetate (GA) on thrombin-induced expression of activation marker CD31 and active form of aIIbb3
integrin on the surface of mouse platelets. Mouse platelets were isolated and pretreated with PBS or GA (50 mg/ml) for 30 min. After
pretreatment with PBS or GA, platelets were activated with thrombin and then analyzed for the expression of activation markers by three-color flow
cytometry as for Fig.2. (A, C) Histograms for CD31 (A, solid lines), or active form of aIIbb3 integrin (B, solid lines), or proper isotype control (dotted
lines) expressions are shown for CD41
+CD61
+ gated mouse platelets. Mean fluorescent intensity (MFI) of activation marker expression is shown in
upper right corner of each histogram. Mean 6 S.E. of four separate experiments is shown in (B) and (D) (*, p,0.05).
doi:10.1371/journal.pone.0096256.g003
Table 1. Statistical analysis of effects of glatiramer acetate (GA) on thrombin-induced CD62P upregulation and platelet aggregate
formation for human and mouse platelets
1.
Human Platelets Mouse Platelets
Control (PBS) Glatiramer acetate
2 Control (PBS) Glatiramer acetate
3
CD62P (MFI)
4 378624 24469
5*** 123632 4265
6*
Aggregates (%)
7 18628 61
8** 21637 62
8**
1Human or mouse platelets were stimulated with thrombin in the presence of GA vs. Control (PBS) as described in Methods.
2Optimal concentration of GA is 100 mg/ml for human platelets.
3Optimal concentration of GA is 50 mg/ml for mouse platelets.
4Mean fluorescence intensity (MFI) of CD62P expression on the surface of CD42a
+CD61
+ gated human or CD41
+CD61
+ gated mouse platelets was analyzed by FACS as
described in Methods. Mean 6 S.E. of five separate experiments is shown.
5***, P,0.001.
6*, P,0.05.
7Percentages (%) of FCS
hiSSC
hi aggregated CD42a
+CD61
+ gated human or CD41
+CD61
+ mouse platelets was analyzed by FACS as described in Methods. Mean 6 S.E. of
five separate experiments is shown.
8**, P,0.01.
doi:10.1371/journal.pone.0096256.t001
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neuroinflammation in the EAE model [11]. Giving the fact that
GA effectively suppressed EAE [12], one potential mechanism of
GA action on reduction of EAE severity and possibly MS is by
decreasing platelet activation and their communication with
leukocytes.
We believe that the effect of GA on platelets is beneficial for
MS, since platelets play a pathogenic role in EAE model [10,11].
Also GA might have a beneficial cardiovascular effect by reducing
thrombosis. Similarly to our findings with GA, Nakano et al.
showed that estrogen decreased the Ca
2+ influx in thrombin-
induced platelets [23], and suggested a beneficial role for
hormonal replacement therapy on the prophylaxis of thrombosis
in post-menopause women [23].
Apart from possible beneficial effects, GA action on platelets
especially at high doses (more than 0.5 mg/ml) could explain some
of the side effects of GA injections. For example, necrotic lesions
with the signs of vein thrombosis were found at the sites of
injections in both IFN-b and for GA treatment [17,18]. This goes
along with our observation that IFN-b (at concentration of 100 U/
ml) and GA (at high concentrations, .0.5 mg/ml) increased
platelet activation. It was also demonstrated that GA may cause
specific symptoms such as chest pain, flushing, dyspnea, and
anxiety [24]. As we demonstrated previously in mouse model,
dyspnea and restless behavior are both associated with massive
platelet activation/degranulation and associated with the release of
potent mediators from platelets such as histamine [11]. Other
investigators found that in humans massive platelet activation/
degranulatuion is caused by the administration of radiographic
contrast media into blood vessels, indicating that human platelets
may degranulate in response to the injection of chemical
substances [25]. According to our study, we believe that platelets
should not be exposed to high concentrations of GA in order to
decrease side effects of GA injections.
Taken together, our study demonstrated a new possible
mechanism of suppression of CNS autoimmune inflammation by
GA via targeting platelet activation. We believe that the results of
our study will allow a better understanding of the therapeutic
effects of GA, with an important implication of improving the
effectiveness of this drug and reducing its side effects during
treatment of MS.
Conclusions
The findings in this study demonstrated that GA suppresses
platelet activation. These results suggest a new possible mechanism
of EAE/MS suppression by GA by targeting platelets. Although it
remains unclear whether the effect of GA on platelets plays a
primary or secondary roles role in MS therapy when compared to
other GA-affected cell types such as lymphocytes, this study
provides a new application for GA to modulate platelet functions
during neuroinflammation or other pathologies.
Materials and Methods
Antibodies and reagents
Thrombin was purchased for Sigma. Human IFN-b was
purchased from PBL Interferon Source. Mouse IFN-b was
purchased from R&D Inc. Anti-human CD42a-PeCP, CD62P-
FITC, CD63-PE, and FITC conjugated PAC-1 antibodies
(recognize active form of human aIIbb3 integrin) were purchased
form BD Biosciences. Anti-mouse CD31-PE, CD41-PE, CD61-
FITC, CD62P-Biotin, CD86-PE antibodies, and Streptavidin-
APC were purchased form BD Biosciences. Anti-mouse F4/80-
APC and CD41-APC antibodies were purchased from eBios-
ciences. Anti-mouse CD11b-AF488, and MHC class II-PE-Cy5
antibodies were purchased from Biolegend. PE conjugated JON/
A antibodies (recognize active form of mouse aIIbb3 integrin) and
fluorescently labeled anti-CD42c antibodies for in vivo labeling of
mouse platelets were purchased from Emfret Analytics Inc. Fura-
2M probe, a membrane-permeable derivative of Fura-2, was
purchased from Molecular Probes. GA (Copaxone
TM) was
purchased from Teva. Undiluted Copaxone (20 mg/ml) was
stored at +4uC. For experiments GA was diluted to proper
concentrations in PBS, stored at room temperature and used
within 12 hours.
Figure 4. Effect of glatiramer acetate (GA) on thrombin-
induced platelet aggregate formation. Human (A) or mouse (B)
platelets were isolated as described in Methods and were pretreated
with PBS or various concentrations of GA (20–500 mg/ml) for 30 min.
After pretreatment with GA, platelets were activated with thrombin and
then analyzed by FACS for aggregate formation as described in
Methods. Contour plots for forward scatter (FSC; x-axes) vs. side scatter
(SSC; y-axes) parameters are shown for CD42a
+CD61
+ gated human (A)
or CD41
+CD61
+ gated mouse (B) platelets. Percentages of FCS
hiSSC
hi
aggregated platelets are shown on a top of square gates of contour
plots. Representative experiment of five is shown.
doi:10.1371/journal.pone.0096256.g004
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For the isolation and analysis of platelets, peripheral blood
samples were drawn using 10 ml collecting tubes with EDTA (BD
Biosciences) from healthy control subjects as described in our
previous study [11]. Mouse platelets were isolated from C57BL/6
(B6) mice as described previously [11]. The analysis of platelet
surface marker expression and Ca
2+ influx was preceded by the
pretreatment with GA or IFN-b for 30 min and activation with
thrombin and was performed and presented as described in details
in our previous work [11] and the work by Nakano et al [23].
Blood samples were kept at room temperature and platelets were
analyzed within 1–3 hours after blood collection.
Platelet aggregation
For analysis of platelet aggregation by FACS, mouse or human
platelets were incubated with PBS or Copaxone for 30 min,
activated with thrombin (0.1 U/ml), and stained with anti-CD61
and anti-CD41 antibodies (mouse), or anti-CD42a and anti-CD61
antibodies (human) as described [11]. The samples were analyzed
by two-color flow cytometry. Gated CD42a
+CD61
+ human or
CD41
+CD61
+ mouse platelets were analyzed for the forward/side
scatter parameters as indicators of the platelet shape change and
aggregation as described earlier [11]. Analysis of platelet
aggregation under flow conditions was performed as originally
described [26–28] with minor modifications. Mouse blood was
collected using sodium citrate as anticoagulant, whole blood
samples were incubated with PBS or with Copaxone for 30 min at
room temperature, then platelets were pre-labeled with antibodies
for in vivo mouse platelet labeling (Emfret) at room temperature
for 15 min. After which, the blood samples were perfused through
the flow chamber with slides coated with mouse fibrillar collagen
at a shear rate of 1200 s
21 for 5 minutes. After perfusion, the slides
were removed from the camera, thoroughly washed with PBS,
fixed with PBS with 1% paraformaldehyde overnight and
analyzed by fluorescent microscopy. Relative sizes of thrombi
were measured using ImageJ software.
Co-culture of platelets with macrophages
Peritoneal macrophages were isolated from C57BL/6 mice as
we described in our previous experiments [29] and were cultured
alone (0.5610
6/well in 24-well plate) or co-cultured with
autologous platelets at the ratio of 1:20 for 24 hours with or
without Copaxone (50 mg/ml). After 24 hours of single culture or
co-culture with platelets, macrophages were washed and stained
for CD11b, F4/80, CD86 and MHC class II similarly as described
[29] and analyzed by 4-color cytometry. CD11b
+F4/80
+ gated
macrophages were analyzed for the expression of CD86 and
MHC class II. Fc receptors on macrophages were blocked using
anti-FcR blocking antibodies to avoid non-specific labeling (BD
Biosceneces).
Analysis of mouse tail bleeding
C57BL/6 mice were purchased from Jackson Laboratories. For
the assessment of platelet activation in vivo, mice were injected with
GA i.v. (200 ml/mouse 3.5 mg/kg for i.v., and 400 ml/mouse
12.5 mg/kg for s.c. injections) and 30 min (for i.v.) or 60 min (for
s.c.) later the tail was cut approximately 5 mm above the tail end
and immersed into saline similarly as described in our previous
study to determine the duration of the bleeding period [11]. IFN-b
was administered i.v. at a dose of 2610
4 U per mouse. The
Figure 5. Effect of glatiramer acetate (GA) on platelet adhesion to collagen and aggregation under flow conditions. Whole mouse
blood samples were collected from normal C57BL/6 mice using sodium citrate as anticoagulant and pretreated with PBS or GA (50 or 100 mg/ml) for
30 min as described in Methods. After pretreatment with PBS or GA, the whole blood samples were labeled with platelet-specific antibodies and then
perfused through the camber with collagen coated glace slides as described in Methods. Collagen coated slides with aggregated pre-labeled platelets
were washed, fixed and subsequently analyzed using fluorescence microscopy. Representative immunofluorescent images for samples treated with
PBS or GA (50 or 100 mg/ml) are shown in (A). Average size of thrombi 6 S.E. is shown in (B).
doi:10.1371/journal.pone.0096256.g005
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preliminary experiments as effective and well tolerated by animals.
Ethics
Use of human platelets from peripheral blood samples of
anonymous healthy individuals for in vitro experiments was
approved by the institutional review boards of the Brigham and
Women’s Hospital and all healthy subjects provided written
informed consent prior to enrollment into study. The data from
human blood samples was obtained and analyzed without records
of any personal information to ensure complete anonymity. All
animal protocols were approved by the Harvard Medical School
Institutional Animal Care and Use Committee and Chinese
University of Hong Kong Animal Ethics Committee. For
experiments that involved pain and distress the appropriate
anesthetic and analgesic drugs were used. Euthanasia was
performed by using carbon dioxide.
Statistical analysis
Student’s t-test and Mann Whitney u-test were used to validate
the significance of the observed differences. A p-value of less than
0.05 was considered statistically significant.
Figure 6. The role of glatiramer acetate (GA) in platelet-dependent activation of macrophages in vitro. Mouse peritoneal macrophages
were isolated and cultured alone or co-cultured with autologous platelets with or without glatiramer acetate. After 24 hours of single culture or co-
culture with platelets, macrophages were stained for CD11b, F4/80, CD86 and MHC class II and analyzed by four-color flow cytometry as described in
Methods. (A) Histograms for CD86 or MHC class II (solid lines) or proper isotype control (dotted lines) expressions are shown for CD11b
+F/80
+ gated
macrophages. Percentages of positive cells are shown on the top of each histogram (B, C) Mean 6 S.E. of three experiments is shown (*, p,0.05 and
***, p,0.001). Abbreviations: MPh, macrophages; GA, glatiramer acetate, Plat, platelets.
doi:10.1371/journal.pone.0096256.g006
Figure 7. Analysis of bleeding time in mice after administration
of glatiramer acetate. Mice were administrated intravenously or
subcutaneously with GA, or IFN-b, or PBS, and 30–60 minutes later, tail
bleeding test was performed as described in Methods. Duration of
bleeding (y-axis, seconds) is shown. Mean 6 S.E. of total 9–12 individual
animal in each group of three separate experiments is shown (***, p,
0.001).
doi:10.1371/journal.pone.0096256.g007
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Figure S1 Effect of glatiramer acetate (GA) on throm-
bin-induced expression of activation marker CD63 and
active form of aIIbb3 on the surface of human platelets.
Human platelets were isolated and pretreated with PBS or
glatiramer acetate (100 mg/ml) for 30 min ad described in Methods.
After pretreatment with GA, platelets were activated with
thrombin (0.1 U/ml) and then analyzed by three-color flow
cytometry as for Fig.2. Representative histograms of expressions of
active form of aIIbb3 integrin (left histograms; solid lines) or CD63
(right histograms; solid lines) or proper isotype controls (dotted
lines) are shown for CD42a
+CD61
+ gated human platelets.
(TIF)
Figure S2 Effect of IFN-b on thrombin-induced surface
expression of CD62P in mouse platelets. Mouse platelets
were isolated as described in Methods and were pretreated with PBS
or IFN-b (100 U/ml) for 30 min. After pretreatment with PBS or
IFN-b, platelets were activated with thrombin and then analyzed
by FACS as for Fig. 2. (A) Histograms for CD62P (solid lines) or
isotype control (dotted lines) expressions are shown for
CD41
+CD61
+ gated mouse platelets. Mean fluorescent intensity
(MFI) for CD62P expression is shown in upper right corner of
each histogram. (B) Mean 6 S.E. of four separate experiments is
shown (*, p,0.05).
(TIF)
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